28,465 Shares in CorMedix Inc. (NASDAQ:CRMD) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in CorMedix Inc. (NASDAQ:CRMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 28,465 shares of the company’s stock, valued at approximately $107,000.

Several other institutional investors also recently made changes to their positions in CRMD. GSG Advisors LLC lifted its stake in shares of CorMedix by 65.0% in the fourth quarter. GSG Advisors LLC now owns 49,500 shares of the company’s stock valued at $177,000 after purchasing an additional 19,500 shares during the period. Vanguard Group Inc. increased its holdings in CorMedix by 3.8% in the third quarter. Vanguard Group Inc. now owns 2,650,748 shares of the company’s stock valued at $9,808,000 after buying an additional 97,451 shares in the last quarter. Deutsche Bank AG lifted its position in shares of CorMedix by 18.2% during the 3rd quarter. Deutsche Bank AG now owns 28,627 shares of the company’s stock valued at $106,000 after acquiring an additional 4,401 shares during the period. Ameriprise Financial Inc. purchased a new stake in shares of CorMedix during the 3rd quarter worth approximately $40,000. Finally, AQR Capital Management LLC purchased a new stake in shares of CorMedix during the 3rd quarter worth approximately $58,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CorMedix

In other news, CEO Joseph Todisco purchased 13,561 shares of the stock in a transaction dated Wednesday, March 13th. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $50,718.14. Following the completion of the acquisition, the chief executive officer now directly owns 352,839 shares in the company, valued at approximately $1,319,617.86. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 3.60% of the stock is owned by insiders.

CorMedix Stock Performance

CRMD stock opened at $5.28 on Friday. The stock’s 50 day moving average price is $4.05 and its 200 day moving average price is $3.63. The firm has a market cap of $289.40 million, a P/E ratio of -5.74 and a beta of 1.86. CorMedix Inc. has a 1 year low of $2.57 and a 1 year high of $7.00.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). On average, research analysts predict that CorMedix Inc. will post -0.83 earnings per share for the current year.

Analyst Ratings Changes

CRMD has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of CorMedix in a report on Tuesday, April 9th. Truist Financial cut their price target on CorMedix from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, January 31st. JMP Securities reiterated a “market outperform” rating and issued a $19.00 price objective on shares of CorMedix in a research report on Tuesday, April 9th. Finally, Royal Bank of Canada dropped their target price on shares of CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.